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Background: Lung diffusion measurements are commonly used for lung function diagnostics. The usage of nitric 
oxide (NO), in addition to carbon monoxide (CO) during a lung diffusion measurement, could lead to a better 
understanding of the process of diffusion. Research Question: This study investigated whether the two on the 
market available instruments for DLNO measurement (‘MasterScreenTM’ (MS) OFT Pro (Jaeger, Switzerland); 
‘HypAir’ (HA) (Medisoft, Dinant, Belgium)), measure identical at the same time at the same place with the same 
protocol and with identical subjects. Method: This study followed a single-center randomized cross-over design 
carried out at the University Hospital of Zurich. 35 healthy subjects of mixed age and sexes were included and 
randomly allocated to perform slow spirometry, forced spirometry and lung diffusion measurements on either 
one of the devices. After completing all tasks, the participants performed the exact same maneuvers on the 
leftover device. The primary outcome was lung diffusion capacity for nitric oxide (DLNO). Secondary outcomes 
were lung diffusion capacity for carbon monoxide (DLCO), alveolar volume (VA) and breath hold time (BHT). 
Comparison of primary and secondary outcomes between both devices were calculated by using a linear mixed 
model. Results: The primary outcome DLNO showed a highly significant difference between the HA and the MS 
device. The mean difference was 24.1 mL/min/mmHg with a 95%CI of 21.8-26.4 mL/min/mmHg (p<0.0001). For 
DLCO the difference was not significant with a mean difference of -0.228 mL/min/mmHg (95%CI: -0.571 
mL/min/mmHg and 0.116 mL/min/mmHg; p>0.2). The mean difference in alveolar volume between both devices 
was 0.484 L (95%CI: 0.447-0.512 L; p<0.0001). Interpretation: Although both devices show similar DLCO values, 
DLNO and VA showed systematic clinically relevant differences. There is no reasonable explanation to justify the 
difference. 
Clinical Trial Registration: NCT04016597 
 
Abbreviation List 
BHT Breath hold time 
BMI Body-mass-index 
CO Carbon monoxide 
DLCO Lung diffusion capacity with carbon monoxide 
DLNO Lung diffusion capacity with nitric oxide 
HA  Device: HypAir 
HE Helium 
ICC Intra class correlation 
MS Device: MasterScreen 
NO Nitric oxide 
SD Standard deviation 
SDws Within-subject standard deviation 
VA Alveolar volume 
95%CI 95 percent confidence interval 





Lung-diffusion measurement analyzes the ability to absorb gases the air we breathe into the 
bloodstream.1 This is one of the standard procedures in lung function diagnostics along with 
the body plethysmography and spirometry and is used in a wide variety of pulmonary 
disorders like chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis.2–5 In 
current lung diffusion measurement carbon monoxide (CO) is added to the inhaled air to 
measure the difference of particles after exhalation within the exhaled air (DLCO).6 
In contrast to DLCO, the lung diffusion capacity measurement with nitric oxide (DLNO) also 
uses the gas nitric oxide (NO) in addition to CO. This technique allows a more differentiated 
view on various reasons of a hindered gas diffusion.7 It could help to better understand 
problems during the gas diffusion. This procedure in combination with the existing DLCO 
method could lead to a better understanding of lung diseases and could become of great value 
in diagnostic procedures. 
By now only a small number of references-values for the DLNO method have been published 
and most of these include a limited number of subjects.8–11 In the study of Zavorsky et al. 
(2017) the authors pooled data from previously held studies by Aulani et al. (2010), van der 
Lee et al. (2006) and Zavorsky et al. (2008) to create a bigger and therefore more 
representative pool of reference-values.8,10–12 This was done although these reference-values 
were created with different protocols and obtained by different devices. In the study done by 
Munkholm et al. (2018) the researchers compared their obtained data with every single set of 
reference-values pooled by Zavorsky.9 They illustrate that every single set of reference-values 
shows different means of the DLNO values. The authors state that possible explanations for 
these differences might be different protocols, different equipment as well as different 
populations.9 
So far, a protocol has been published to standardize the DLNO measurement to eliminate 
future methodological bias11. Still different equipment is used internationally to measure the 
diffusing capacity and therefore leave room for potential bias. There are two commercially 
available devices on the market: ‘MasterScreenTM’ (MS) OFT Pro (Jaeger, Switzerland) and 




‘HypAir’ (HA) (Medisoft, Dinant, Belgium). Both devices measure the NO concentration with 
an electrochemical cell. 
A previously conducted pilot study, which aimed at a comparison of both devices reveals that 
the HA device constantly measures higher DLNO values (Radtke unpublished). Up to this point 
there has been no research published regarding a comparison of both devices, even though 
both are used within the field of research. 
The aim of this study was to answer the question of whether the two on the market available 
instruments for DLNO measurement, measure identical at the same time at the same place 
with the same protocol and with identical subjects. 
Method: 
Design: 
This study followed a single-center randomized cross-over design carried out at the University 
Hospital of Zurich. All included participants were invited to the research laboratory to perform 
spirometry as well as the diffusion capacity measurements. Subjects were informed about the 
project and asked for their consent to participate. After the randomization the participants 
performed the spirotemtries and the diffusion measurement on either one of the two devices. 
After completing all assessments on the first device the participants performed the exact same 
measurement on the second device. See section ‘Protocol’ for detailed information regarding 
the procedure. 
Participants: 
This study included 35 healthy non-smoking adults of both sexes and varying ages (>= 18 
years). Recruitment was done by personal invitation or email. The Epidemiology, Biostatistics 
and Prevention Institute at the University of Zurich, the physiotherapy master’s program at 
the Zurich University of applied Sciences (ZHAW) were places for recruitment. Inclusion 
criteria were >= 18 years, Caucasian ethnicity. Exclusion criteria were smoker, individuals with 
known pulmonary or cardiovascular disease, acute respiratory symptoms, operations or 
radiation therapy of the chest, a body mass index (BMI) >30kg/m-2 and pregnancy. The 




subjects of the study live in Zurich or the surrounding area. Characteristics of the studied 
population are seen in Table 1. 
Table 1 
Patient characteristics at baseline 
Variables HA then MS MS then HA Complete 
Subjects (n) 22 (63%) 13 (37%) 35 
Sex    
male 11 (50%) 6 (46%) 17 (49%) 
female 11 (50%) 7 (54%) 18 (51%) 
Age (years) 40.8 ±2.9 (22-62) 38.8 ±5.2 (21-75) 40.0 ±15.5 (21-75) 
Height (cm) 175.5 ±2.5 (159-200) 172.8 ±2.7 (159-196) 174.5 ±10.1 (159-200) 
Weight (kg) 73.2 ±2.4 (53-91) 63.5 ±3.4 (47-91) 69,6 ±12.4 (47-91) 
BMI (kg*m2) 
 
23.7 ±0.6 (18.6-28.1) 21.1 ±0.6 (17.1-23.7) 22,7 ±2.8 (17.1-28.1) 
RHR 71.6 ±2.4 (50-95) 68.5 ±3.0 (51-88) 70.5 ±11.0 (50-95) 
Spo2 (in %) 97.7 ±0.2 (95-99) 97.3 ±0.3 (94-99) 97.5 ±1.0 (94-99) 
 
Data are mean inclusive standard deviation and range. BMI, body mass index; RHR, resting heart ratio; Spo2, 




The allocation list was computer generated with the online randomization tool accessible at 
http/www.randomizer.org. Simple randomization has been used. The generated list contained 
numbers ranging from one to two. The number one implied the given subject started with the 
MS device and went on with the HA device. The number two indicated to start with the HA 
device and afterwards the MS device. The list was created by an independent person not 
involved in the study. Access to the list was restricted to two independent persons not 
involved in this study. Allocation concealment was ensured using central randomization, by 




ad hoc request of the allocation sequence via phone. Blinding was not possible due to the 
protocol.  
Ethics: 
Since this study is of a methodological design focusing on a comparison of two devices and as 
it is not used for diagnostic purposes or treatment advice, it does not fall within the scope of 
the Human Research Act (HRA). Therefore, no authorization by the ethics committee was 
required. This has been examined and registered by the ethics committee of the canton of 
Zurich by means of a clarification of responsibilities (2019-02026). 
Quality control: 
The quality and reproducibility of the measurements were ensured by the following means. 
The devices were reviewed, and presets were made by technicians in advance of the study, to 
ensure that the devices were working properly. The software used for the HA device was 
‘Expair Version 1.32 05’ for the MS device ‘sentry Suite Version 3.0.2’ was used.  Each day the 
devices were manually calibrated using the three-flow method and a calibrated three liters 
syringe. Besides volume calibration, a gas calibration was performed using automated 
procedures for helium (He), carbon monoxide (CO), oxygen (O²), and methane (CH4). To ensure 
a detection of any major fluctuations in DLNO values during the course of the study, biological 
control measurements were performed. Therefore, the same subject performed every week 
all measurements on both devices, during the entire data collection period. This was done by 
two different subjects of both sexes (male, age: 26 years; female, age: 54 years). 
Protocol: 
In advance of the measurement, no intensive physical activities were allowed for at least 24 
hours prior to testing. Coffee and meal consumption have been restricted three hours before 
undergoing the measurements. After welcoming the subject, the ad-hoc randomization has 
taken place by support of the statistical department. The aim of the study was explained to 
the subjects and the inclusion and exclusion criteria were checked. General information like 
bodyweight (nearest to 100g), standing height (nearest to 1 mm), sex, date of birth, resting 
heart rate (after a minimum of five minutes rest), oxygen saturation (in percent) as well as air 




temperature (in degrees Celsius) and air-humidity (in percent) were noted. The measurements 
were taken at 430 meters above sea level. During the entire measurement, the subjects were 
asked to stay seated and could drink one cup of water in between the measurements. 
According to the randomization process, either one of the devices was used first. In the 
beginning, a slow spirometry was performed, and it was repeated until three reproducible 
measurements were collected. Afterwards, the forced spirometry was performed repeatedly 
until three reproducible measurements were gathered. Both spirometries were performed 
according to standardized protocols.13 Following the forced spirometry, the lung diffusion 
capacity measurement was performed. Like the spirometry, standardized protocols were used 
for DLNO measurement and the maneuver was in the similar way repeatedly performed until 
three reproducible measurements (all DLNO scores within a range of 17 mL/min/mmHg), were 
collected.14 In between the separate measurements a five-minute break as wash-out period 
was held. There were no changes to methods after trial commencement. 
Outcomes: 
The primary outcome of the measurements is DLNO (in mL/min/mmHg). Secondary outcomes 
are: DLCO (mL/min/mmHg), alveolar volume (VA; in liters) and breath-hold time (BHT; in 
seconds). Outcomes are obtained by stated DLNO devices. General information such as height, 
age and body weight were noted. Further values, for example BMI (body-mass-index) were 
calculated using patient characteristics. 
Statistics: 
Since there is no data available for of a power calculation, an a priori pilot study was used as 
a basis. From the values of the pilot study the ICC (Inter-Class-Correlation) for the DLNO values 
could be calculated as 0.96 (95% confidence interval (95%CI) 0.0.85-1). Because in the pilot 
study all participants were familiar with the procedure and that other external factors had an 
influence on the result, a more conservative approach was chosen for this study. For a desired 
ICC of 0.85 (95%CI 0.75-0.95) 31 participants were required (ICCest Calculation – Calculated 
with nQuery Advisor 7.0). Due to possible drop-out, 35 participants were recruited. 
Comparison of primary and secondary outcomes between both devices will be calculated by 
using a linear mixed model (DLNO as primary endpoint) adjusting for device (Jaeger vs 




Medisoft, coded as 0, 1) and period (machine with which the participant started) as fixed 
effects AND random intercept for each subject. 
The SPSS version 23 (IBM Corp. Armont, NY, USA) and R Version 3.6.3 (R-project, Vienna, 
Austria) are used for statistical evaluations. Three reproducible measurements per instrument 
(MS/HA) are at minimum required for calculation. The ICC 3.1 calculation (two way-mixed 
model) was used with its associated 95% confidence interval. Precision of DLNO values were 
be quantified by the within-subject standard deviations (SDws = root mean square error) 
calculated by the root-mean-square (RMS) method and the coefficient of variation.15 
Reproducibility was calculated with 1.96*1.96*√2*SDws (95% confidence interval). Intra-
device reproducibility was calculated as 1.96 * √2 *SDws (95% level of confidence).16 Intraclass 
correlation coefficients (ICC’s) and their 95% CI’s were calculated for the primary outcome 
using a two-way mixed model [consistency, single measurement, (ICC, 3.1)].17 Interpretation 
of ICC’s is based on Cicchetti.18  





All participants completed all assessments and no participant was excluded from this study. 
No adverse events occurred during the entire data collection period. All participants were 
recruited and measured between October 2019 and January 2020. Trial was ended after 
completion of all measurements. No changes to outcomes after trial commencement were 




Flow diagram showing detailed information about patient follow-up. n, number 
of participants 




Both sets of equipment passed all the tests performed. 22 Subjects were allocated to begin 
with the MA device, 13 allocated to begin with HA device. Subjects showed a mean resting 
heart rate of 70.5 (Standard deviation [SD]: 11.02; range: 50-95) and a peripheral capillary 
oxygen saturation of 97.7 (SD: 1.01; range: 94-99). Mean laboratory environmental conditions 
were: Temperature 23.7 °Celsius (SD: 1.66; range 21-27); Humidity 36.7 (SD: 8.96; range: 22.5-
51). Allocation specific details are presented in Table 1. 
The primary outcome DLNO difference between the HA and the MS device showed a highly 
significant difference. The mean difference was 24.1 mL/min/mmHg with a 95%CI of 21.8-26.4 
mL/min/mmHg (p<0.0001). In figure 2 all DLNO results for each subject are plotted in ranked 
order. 
In contrast to DLNO, the DLCO measurement show no significant difference with a mean 
difference of -0.228 mL/min/mmHg and a 95% confidence interval between -0.571 and 0.116 
mL/min/mmHg (p>0.2). The mean difference in alveolar volume between both devices was 
Figure 2: 
Ranked DLNO results 
All DLNO measurements per subject id in ranked order for DLNO. DLNO, lung diffusion capacity 
measurement with nitric oxide; Jaeger, MasterScreenTM (MS) device; Medisoft, HypAir (HA) device. 




0.484 L (95%CI: 0.447-0.512 L; p<0.0001).  The average Breath-hold-time on the HA device 
was 5.93 ±0.37, on the MS device the BHT was 6.29 ±0.34. Figure 3 shows mean values on 
both devices for DLNO, DLCO and VA. Mean values on both devices are linear connected. 
Figure 3 
Linear connected means 
 
Linear connected means between both devices. DLNO, lung diffusion capacity 
measurement with nitric oxide; DLCO, lung diffusion capacity measurement with carbon 










Intra-device variability characteristics are shown in Table 2. All Subjects fulfilled the 
recommended intrasession repeatability criteria for DLNO and DLCO (17.0 and 3.2 
mL/min/mmHg).12,14 The reliability analysis showed an ICC for the DLNO value of 0.979 with a 
95% confidence interval of 0.959-0.990. 
Table 2 
Intra-session variability 
Variables MasterScreenTM (MS) HypAir (HA) 
Measure-
ment error a 
Repeatability b CV 
(%) 
Measure-
ment error a 











1.05 2.92 3.41 
VA (L) 0.11 0.30 1.7
8 
0.11 0.30 1.78 
Data were measured at a target breath-hold time of 5 s. CV, coefficient of variation; DLNO, pulmonary diffusing 
capacity for nitric oxide; DLCO, pulmonary diffusing capacity for carbon monoxide; VA, alveolar volume.  
a The measurement error (or within-subject standard deviation, SDws) was calculated by the root-mean-square 
(RMS) method.  
b Repeatability of gas diffusing measurements was calculated as the SDws from three single-breath tests for 
each study visit separately and multiplied by 2.77 (95% level of confidence). 
 
During the time of data collection for biomonitoring, both selected subjects completed each 
eleven biomonitoring assessments. Both subjects showed only little variation within their 
scores during the entire assessment period. Person one showed on the HA device a coefficient 
of variation of 3.17 mL/min/mmHg and a mean deviation of 6.13 mL/min/mmHg for DLNO. 
On the MS device a coefficient of variation of 3.07 mL/min/mmHg and a mean deviation of 
4.56 mL/min/mmHg. Person two showed a coefficient of variation of 2.72 mL/min/mmHg and 
a mean deviation of 2.6 mL/min/mmHg for DLNO. On the MS device person two showed a 
coefficient of variation of 3.06 mL/min/mmHg and a mean deviation of 2.64 mL/min/mmHg. 
 





The aim of this study was to compare two commercially available devices to measure DLNO. 
This study shows that there is a statistically significant difference between both devices if 
comparing for DLNO. The within session repeatability for DLNO is about 17 
mL/min/mmHg.14,19 This study shows a higher mean difference (24.1 mL/min/mmHg; 95%CI: 
20.5-27.6). It indicates that this difference is not only statistical but also clinically meaningful. 
In contrast to DLNO, DLCO show no statistically significant difference. The repeatability of 
DLCO is 2 -2.5 mL/min/mmHg.20 Therefore, DLCO shows no clinical meaningful and no 
statistically significant difference between both devices. The coefficient of repeatability for VA 
for healthy subjects is 144 ml, consequently VA shows statistical significant and clinical 
meaningful differences.21 
It is unclear how this systematic difference can be explained besides measurement 
differences. Both devices were running on the latest software update and have been 
controlled by technicians prior to this study, to ensure both are working properly. Both devices 
use similar electrochemical cells for the DLNO measurement. All instructions on both devices 
have been followed and the entire measurement procedure was held according to the latest 
protocol published by Zavorsky (2017).12 A possible learning effect has been avoided by the 
cross-over study design. A possible carry over effect has been avoided by strict adherence to 
the wash-out period in between every single DLNO measurement and in between switching 
devices. Biomonitoring has been done during the entire data-collection period to detect any 
major fluctuations and have shown no major fluctuations whether in DLNO, DLCO or VA. Since 
there is no gold standard to compare these results with, these results cannot indicate whether 
one of both studied devices measures ‘correctly’. Therefore, no right or wrong can be stated 
by this study. 
In a previous study by Zavorsky and Murias (2007) the intra-session variability of DLNO and 
DLCO was analyzed for 31 healthy subjects using the HA device.19 Their observed intra-session 
variability values for DLNO are comparable to the ones obtained in this study (Repeatability: 
19.5 versus 17.35 mL/min/mmHg). There is no data available for intra-session variability for 




the MS device for healthy subjects. However, in our study, both devices show overall 
comparable intra-session variabilities. 
The difference in calculated BHT can be explained by different software interfaces and slightly 
different instructions. Studies have shown that shorter breath hold times can overestimate 
the diffusion capacity in healthy subjects.22,23 The HA devices scored lower BHT values and 
higher DLNO values. The study of Dressel et al. (2008) showed no statistically significant 
differences in DLNO if comparing a BHT of four to six seconds.22 A comparison between four 
and eight seconds showed a statistically significant difference with an absolute mean 
difference of 8,63 mL/min/mmHg.22 In this study the mean difference in BHT was 0.36 seconds 
and the mean difference in DLNO was 24.1 mL/min/mmHg. Therefore, the difference in BHT 
could only explain a marginal amount of the presented difference. 
This study used different gas canisters with a different amount of helium percentage (10%HE 
for the MS device; 14%HE for the HA device). The usage of a mixture containing 14% Helium 
was recommended by the ‘MediSoft’ company during the purchase of the device. Although it 
is recommended to use 10% HE there are also studies published for DLNO reference values 
using a mixture with 14% HE.10 Helium is used as tracer gas and has no interference with the 
measurement of DLNO. For the calculation of the alveolar volume a helium dilution technique 
was used on both devices. The dilution factor for HE was adjusted according to the mixture 
used for both devices. 
Up to today only a small number of reference values for the DLNO method have been 
published, most of these include a limited number of subjects.8–11 Most of these studies were 
performed in a single laboratory and used only a single device. To increase the amount of 
reference values, studies with larger samples sizes would be necessary. This would exceed the 
possibilities for a single laboratory. Therefore, multicentric studies must be performed to be 
able to test many subjects. Subsequently established data could be pooled to increase 
reference values. This study shows that it is not recommended to pool data collected by both 
devices (MS and HA) to create reference values as it is done before.12 These would not 
represent true reference values for any given population. 




In addition to these findings, it is at this point of time unclear if the same device presents 
similar values given the same circumstances for the same person at two different locations. 
This question must be answered in advance of pooling data from either one of the devices 
from different locations. These findings show that pooling data for reference values is 
currently not accurate. Further research and development must be conducted to allow 
pooling data from different locations. 
One limitation of this study is the missing block randomization. This allowed the allocation to 
exceed a close to 50-50 percent distribution. In this study 63 % were appointed to start with 
the HA device. However, characteristics are well balanced along both sequence groups. 
In conclusion, this study shows that the two on the market available devices for DLNO 
measurement (‘MasterScreenTM’  OFT Pro [Jaeger, Switzerland] and ‘HypAir’ [Medisoft, 
Dinant, Belgium]) present within the same individuals systematic statistical differences for the 
lung diffusion capacity measurement with nitric oxide. There was no clinical meaningful or 
statistical significant difference found for DLCO measurement at the same time. There is no 
reasonable explanation to justify the total amount of detected difference between both 
devices. 
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4. Kritische Würdigung der eigenen Arbeit: 
 
Studie: Comparison of two commercially available devices to measure nitric oxide 
lung diffusing capacity in healthy, non-smoking adults. 
Eigene Leistung: 
Meine eigene Leistung an dieser Forschungsarbeit hat schon im ersten 
Transferpraktikum begonnen. Ich stieg in ein schon geplantes Projekt zwischen den 
Standorten der Spitäler in Paris, Aachen und Zürich ein. Bei diesem Projekt, welches 
später als Pilotstudie eine Basis für diese Masterarbeit legte, wurde ein Vergleich 
zweier DLNO Messgeräte an den oben genannten Standorten durchgeführt. Meine 
Rolle bei diesem Projekt war die eines Probanden. Auf Basis der Erkenntnisse dieser 
Pilotstudie wurde binnen des Instituts für Epidemiologie, Biostatistik und Prävention 
die Forschungsfrage dieser Studie entwickelt. Da ich schon bei der zuvor 
durchgeführten Pilotstudie teilnahm und daher in diesem Fachgebiet eingelesen war, 
nahm ich dieses Projekt gerne als meine Masterarbeit an. Das Studiendesign stand zu 
Beginn fest, da es um einen Gerätevergleich handelt. Abgesehen vom Design war es 
mir jedoch möglich, Vorschläge für das detaillierte Vorgehen einzubringen und meine 
Meinung zu äußern. So hatte ich zu Beginn den Vorschlag, eine aktivitätsbezogene 
Intervention wie zum Beispiel 20 Kniebeugen miteinzubauen, um den Zusammenhang 
mit der Physiotherapie herzustellen. Nachdem vonseiten der ZHAW entschieden 
wurde, dass eine direkte physiotherapeutische Relevanz nicht mehr obligatorisch sei, 
konnte auf die endgültige Forschungsfrage fokussiert werden. Folglich konnte ich die 
Forschungsfrage ausarbeiten und einen detaillierten Ablauf in Zusammenarbeit mit 
meinem Betreuer planen. Mithilfe einer weiteren Kollegin war es möglich, die 
Messgeräte die Gegenstand der Studie waren, besser kennenzulernen und 
selbstorganisierte Probemessungen durchzuführen. Die Probandenrekrutierung 
außerhalb des Kollegen- und Bekanntenkreises des Institutes und des 
Universitätsspitals lag in meinem Aufgabenbereich. Auch die Durchführung eines 
großen Teils der Datenerhebung, sowie die Dateneingabe befanden sich in meiner 
Verantwortung. Nach Abschluss der Datenerhebung und der ersten Auswertungen 
wurde mit der Fehlersuche und der Problemlösung begonnen. Es mussten potenzielle 




Quellen für die Entstehung des gemessenen Unterschiedes erörtert und der jeweilige 
mögliche Einfluss analysiert werden. Zusammenfassend kann gesagt werden, dass 
die Rahmenbedingungen sowie die Projektidee von meinem Betreuer gestellt wurden, 
ich jedoch binnen dieses Rahmens frei war, Ideen und Alternativen mit einzubringen 
und mitverantwortlich für die Durchführung, Analyse und Interpretation der Studie war.  
 
Offene Fragen:  
Die durchgeführte Studie zeigt auf, dass zwei Geräte binnen des Messverfahrens 
DLNO bei gleichen Individuen und Umgebungsfaktoren deutlich unterschiedliche 
Ergebnisse erzeugen. Nun stellt sich die Frage, ob zwei identische Geräte an 
verschiedenen Standorten vergleichbar messen. Falls dies der Fall sein sollte, könnte 
man Daten poolen, die auf einem identischen Gerät erhoben wurden. Da es momentan 
nur zwei auf dem Markt frei erhältliche Messgeräte gibt, könnte es trotz des 
Ergebnisses aus dieser Studie eine Möglichkeit geben, größere Datensätze als 
Referenzwerte zu generieren. Aufgrund verschiedener Geräte- und Softwareversionen 
der zwei Hersteller, wäre auch diesbezüglich ein Vergleich sinnvoll. 
 
Kritische Betrachtung:  
Offen bleibt zudem die Frage, ob innerhalb dieser Studie eine Einstellung an einem 
Gerät übersehen wurde, oder ob ein anderer unbekannter Fehler gemacht wurde. 
Trotz der Überprüfungen der Techniker und mehrfacher Kontrolle, sowie protokollierte 
Vorgehensweisen und Biomonitoring bleibt immer die Möglichkeit bestehen, dass eine 
mögliche Fehlerquelle nicht erkannt wurde. Diese Gefahr besteht jedoch in jeder 
durchgeführten Studie und nur eine Replikationsstudie könnte diese Art potenzieller 
Fehlerquellen aufdecken oder eliminieren. 
Die Durchführung dieser Studie fand im Rahmen des Masterstudiums Physiotherapie 
der ZHAW statt. Daher war auch der zeitliche Ablauf sehr eng an die 
Rahmenbedingungen der ZHAW und der nebenbei anfallenden Studienlast gebunden. 
Prüfungsphasen, Semesterferien und Module, die auf spezifische Abschnitte der 
Masterarbeit zugeschnitten waren, bestimmten den zeitlichen Ablauf zu einem 
gewisses Maß. Hätte diese Bindung nicht existiert, wäre es möglich gewesen, diese 




Forschungsarbeit in einem kürzeren zeitlichen Rahmen durchzuführen. Ein weiterer 
Grund, der für eine zwischenzeitliche Zwangspause gesorgt hatte, war eine leere 
Gasflasche und die entsprechende Lieferzeit der besagten Flasche. Nach einer 
fünfwöchigen Lieferzeit wurde diese kurz vor Weihnachten 2019 geliefert. Dies führte 
dazu, dass die Datenerhebung erst Mitte Januar anstelle von November/Dezember 
beendet werden konnte. Ab Februar entstanden erneut Schwierigkeiten bezüglich 
Besprechungsterminen und Terminen im Labor, aufgrund der Corona Pandemie. 
 
Alternative Vorgehensweise: 
In einer zukünftigen Replikationsstudie könnten verschiedene Maßnahmen getroffen 
werden, um einen Gerätevergleich zu optimieren. Zum einen wäre es wichtig, bei 
beiden Geräten die identische Gas-Mischung zu verwenden. Beide Geräte wurden 
jedoch in dieser Studie auf die jeweilige Gaskonzentration kalibriert, jedoch würde dies 
ein methodologisch optimierten Vergleich gewährleisten. Des Weiteren sollte eine 
externe Messmethode verwendet werden, um die Atem-Anhalte-Zeit (BHT) zu 
regulieren. Dies könnte beispielsweise mithilfe eines akustischen Signals gehandhabt 
werden. Ein solches Vorgehen würde den Einfluss des Programm-Interfaces 
minimieren. Die verwendeten Gasflaschen sollten regelmäßig kontrolliert werden und 
frühzeitig benötigte Gase bestellt werden. Eine weitere mögliche Verbesserung wäre, 
die Beschränkung der Verantwortlichkeit auf eine Person für die Durchführung der 
Messung zu kürzen. Dies würde einen potenziellen Einfluss von verschiedenen 
Messpersonen auf die Datenerhebung beseitigen. Im Rahmen dieser Masterstudie 
war dies aus Zeitgründen nicht möglich. 
 
Relevanz der Masterarbeit: 
Diese Studie hat nur bedingt eine Relevanz für die Physiotherapie. Innerhalb der 
Pneumologie und der Lungenfunktionsdiagnostik zeigt diese Studie jedoch eine sehr 
viel größere Relevanz. Wie in der Einleitung der Forschungsarbeit schon beschrieben, 
könnte dieses Verfahren helfen die Lungendiffusion und Krankheiten, bei denen dieser 
Prozess eingeschränkt ist, besser zu verstehen. Referenzwerte sind ein essenzieller 
Bestandteil, um individuelle Ergebnisse klinisch interpretieren zu können. In den 




vergangenen Jahren wurden vermehrt Studien zur Generierung von Referenzwerten 
durchgeführt. Auch wurden diese Ergebnisse schon zusammengeführt, um die 
Aussagekraft zu vergrößern. Unsere Studie zeigt jedoch, dass dieser Schritt 
möglicherweise noch nicht gemacht hätte werden sollen. Wir haben aufgedeckt, dass 
man die Daten von den untersuchten Messgeräten nicht zusammenführen kann. Dies 
könnte später bei klinischer Anwendung im Ernstfall zu einer verfälschten 
medizinischen Diagnostik führen.  
Die Relevanz für den Fachbereich der Physiotherapie besteht darin, dass dieses 
Verfahren gerade bei kardio-pulmonalen Patienten häufig einen elementaren 
Bestandteil darstellt. Daher hilft es zu gewährleisten, dass Patienten beispielsweise 
mit einer COPD, ein evidenzbasiertes diagnostisches Verfahren erhalten.  
Generell ist nach momentanem Forschungsstand der Lungendiffusionsmessung 
mittels Stickstoffmonoxid noch nicht klar, welche Vorteile diese Messmethode mit sich 
bringt und ob diese jemals klinisch in Kombination zur DLCO Anwendung findet. Laut 
aktuellem Wissenstand könnte diese Methode, potenziell zu einem besseren 
Verständnis des Gasaustausches binnen der Lungenfunktionsdiagnostik führen. Diese 
Forschungsarbeit zeigt neue Erkenntnisse auf und beantwortet eine wichtige, bisher 
ungeklärte Forschungsfrage. Insgesamt hilft die durchgeführte Studie das 
Messverfahren mittels Stickstoffmonoxid besser zu verstehen und bringt damit den 
potenziellen Mehrwert einen Schritt näher an den Patienten. 
Persönlicher Bezug: 
Der Fachbereich Lungendiffusion war auch für mich als muskuloskelettaler 
Physiotherapeut etwas Unbekanntes. Nach langer Einarbeit binnen des ersten 
Transfermoduls und der beiden Messungen in Paris und Aachen, hat dieses Thema 
mein Interesse geweckt und ich habe es als sehr abwechslungsreich und 
erkenntniserweiternd empfunden, binnen der Pneumologie eine Forschungsarbeit 
durchgeführt zu haben. Meine bisherige Arbeitserfahrung hat sich sehr auf die 
physiotherapeutische Arbeit in Einzelpraxen konzentriert. Daher stellt diese 
Masterarbeit mit dem Einblick in den Fachbereich der inneren Medizin einen 
interdisziplinären, spannenden und herausfordernden Abschnitt des Masterstudiums 
dar.  
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